Finnish nationwide cohort study of 2,083 under-23-year-old gender-referred individuals (1996-2019) compared with 16,643 matched controls. Gender-referred adolescents showed significantly higher psychiatric morbidity than controls both before (45.7% vs. 15.0%) and ≥2 years after referral (61.7% vs. 14.6%). Those referred after 2010 had greater psychiatric needs than earlier cohorts. Among adolescents who underwent medical gender reassignment, psychiatric morbidity increased markedly during follow-up—rising from 9.8% to 60.7% in feminising gender reassignment and from 21.6% to 54.5% in masculinising gender reassignment. After adjusting for prior psychiatric treatment, all gender-referred adolescents had similarly elevated risks of psychiatric morbidity, with hazard ratios approximately three times higher than female controls and five times higher than male controls. Concludes that severe psychiatric morbidity is common among gender-referred adolescents, appears more prevalent in those referred after the recent surge in referrals, and psychiatric needs do not subside after medical gender reassignment.

This Norwegian cohort study of 1,258 youth referred to the National Center for Gender Incongruence found that 22% were discharged without gender-affirming medical treatment. Of those who started testosterone, 18 females detransitioned (11 due to cessation of transgender identity), though this likely underestimates true detransition rates due to loss to follow-up—patients discontinuing treatment may disengage from care, and treatment outside the clinic system was only captured if clinicians were informed. The study highlights the high continuation rate from puberty blockers to hormones (97%), raising concerns about the pipeline effect, and underscores the need for long-term follow-up given highly variable follow-up durations (3–20+ years), incomplete capture of external treatment, and various treatment trajectories including detransition.

This large-scale study of English primary care records found a 50-fold (5000%) increase in recorded gender dysphoria/incongruence among children and young people aged 0-18 between 2011 and 2021. Prevalence increased from 0.16 to 8.3 per 10,000 persons, with the rise being most pronounced in birth-registered females after 2014. The study also found high rates of co-occurring mental health conditions - 52.7% had records of anxiety, depression or self-harm. Medical interventions were relatively uncommon, with 4.7% prescribed puberty blockers and 8.0% prescribed cross-sex hormones. The authors note the urgent need for better mental health support for this population.

This systematic review and meta-analysis from Archives of Disease in Childhood examined 10 studies on puberty blockers for youth with gender dysphoria. The authors found "considerable uncertainty regarding the effects of puberty blockers" with only "very low certainty" evidence for outcomes including global function, depression, and bone mineral density. Comparative observational studies provided very low certainty evidence, and before-after studies also showed very low certainty. The authors conclude that "methodologically rigorous prospective studies are needed" before these interventions can be confidently recommended.

This comprehensive systematic review and meta-analysis evaluated 24 studies on gender affirming hormone therapy (GAHT) for individuals under 26. The review found mostly "very low certainty" evidence regarding gender dysphoria, global function, and depression. While one study suggested lower odds of depression (OR 0.73), this was rated as low certainty evidence. The authors concluded: "There is considerable uncertainty about the effects of GAHT and we cannot exclude the possibility of benefit or harm. Methodologically rigorous prospective studies are needed to produce higher certainty evidence."

This paper argues that the weak evidence base and profound consequences of gender-affirming interventions for youth call for sensitive psychoanalytic exploration. It critiques how socio-political trends frame deep exploration of why young people seek medical transition as 'off-limits' or conversion therapy. The author notes that politically driven clinicians misrepresent those who explore the meaning of trans identification, minimizing the weak evidence base and serious risks while obscuring psychic pain beneath gender dysphoria.

A qualitative study of six UK females (ages 21-32) who detransitioned after medical interventions. Four narrative themes emerged: limits of medical transition in resolving dysphoria, long-term health concerns about testosterone, social challenges of living as men, and detransition as an ongoing process. Participants reported unmet support needs and highlighted the importance of realistic expectations about transition outcomes.

This Finnish study of nine detransitioners (7 female, 2 male) found all reported that their initial transition was driven not by genuine transgender identity, but by unresolved psychological stressors including childhood trauma, sexual abuse, eating disorders, and borderline personality symptoms. All seven females had 'major' regret with mean regret time of 7 years. Retrospectively, patients identified the need for transitioning stemmed from maturation challenges and attachment issues, not gender dysphoria. The study highlights the critical importance of thorough psychological assessment before medical intervention.

Analysis of boys on puberty blockers, showing persistent damage to spermatogonial stem cells, suggesting irreversible infertility even after discontinuation.

A retrospective study using the TriNetX database (56 US healthcare organizations, over 90 million patients) examining suicide and self-harm risk following gender-affirmation surgery. The study compared 1,501 adults who had gender-affirming surgery and emergency visits against control groups. Key findings: individuals who underwent gender-affirming surgery had 12.12-fold higher suicide attempt risk than those without surgery (3.47% vs 0.29%); compared to tubal ligation/vasectomy controls, risk was 5.03-fold higher before propensity matching and 4.71-fold after matching (3.50% vs 0.74%); results were consistent when using pharyngitis controls. The study concludes that patients who have undergone gender-affirmation surgery show significantly elevated suicide risk, highlighting the need for comprehensive post-procedure psychiatric support.

The Cass Review, published in April 2024, is an independent review of NHS gender identity services for children and young people that recommends a more cautious, evidence-based approach to care. It calls for holistic mental health assessments, improved research on medical interventions like puberty blockers and hormones, and stricter clinical oversight, while emphasizing that the review does not seek to undermine trans identities but rather ensure safe, effective care for a vulnerable and growing patient population.

This systematic review in the Journal of Sexual Medicine examined existing research on detransition rates among individuals who requested or started gender-affirming hormonal treatments. The review found significant gaps in the literature and identified potential sources of bias in different datasets. The author notes that despite recent evidence suggesting benefits of gender-affirming procedures, emerging demands for detransition and reports of regret indicate critical knowledge gaps. The review highlights the need for better long-term follow-up studies to understand the true prevalence of detransition and its underlying causes.

Published in the Hastings Center Report, this bioethical analysis critiques the shift from evidence-based justifications for pediatric gender-affirming care to "autonomy-based" arguments appealing to "embodiment goals." The author argues that recent systematic reviews have concluded the scientific evidence is uncertain, leading some to abandon health improvement as the goal and instead justify interventions through patient autonomy. Gorin concludes these autonomy-based arguments misunderstand the place of autonomy in clinical decision-making and consequently put patients at risk of medical harm.

This paper argues that the actual rates of detransition, discontinuation, and regret are unknown due to significant flaws in existing research. It critiques widely cited studies for issues like short follow-up periods (as regret can take years to surface), high loss-to-follow-up rates, and using samples that don't reflect the recent surge in adolescent cases. The author concludes that claims of very low regret rates are unreliable and that this uncertainty is critical for informed consent.

This study of 68 adolescents at a gender clinic (47% autistic) found that nearly a third (29%) shifted their requests for medical transition. Shifts were more common among nonbinary youth and were considered a 'not uncommon' part of the gender discernment process. The most frequent pattern was withdrawing a request and later resuming it.

A survey study of 78 US young adults (ages 18-33) who previously identified as transgender and stopped identifying as transgender at least six months prior. The study found that most participants (83%) had taken social transition steps and 68% had taken medical transition steps. Key findings include: fewer than 17% met DSM-5 criteria for childhood gender dysphoria, while 53% believed rapid-onset gender dysphoria applied to them; 91% were natal females; participants reported high rates of psychiatric diagnoses prior to trans-identification; psychological health improved dramatically after detransition with decreases in self-harm and gender dysphoria; the most common reason for initial trans-identification was confusing mental health issues or trauma reactions for gender dysphoria; reasons for detransition reflected internal changes rather than external pressures. The study suggests detransition is both possible and beneficial for some individuals.

This commentary argues that the 'gender-affirmation model' is causing iatrogenic harm, as evidenced by a growing number of young detransitioners. The author critiques the model for insufficient psychological assessment, downplaying medical risks, and relying on weak evidence. It calls for recognizing detransitioners as survivors of medical harm and urges open debate and research into the long-term effects of youth transition, noting that many European countries are now adopting more cautious approaches.

This investigative report highlights the growing international debate over medical transition for minors. While US medical bodies endorse 'gender-affirming care,' several European countries (Sweden, Finland, UK) are urging caution due to low-quality evidence. The article questions the claim of a medical consensus, pointing to systematic reviews that find the evidence for hormonal treatments in adolescents to be 'low' or 'very low' quality and noting the lack of long-term outcome data.

This paper argues that detransition has been overlooked by researchers and clinicians, leading to unmet healthcare needs. The authors call for robust, non-politicized research to understand the diverse experiences of those who detransition, noting that current studies are limited by short follow-up times and selection bias. They emphasize that improving care for detransitioners is a necessary part of comprehensive gender care and will ultimately benefit all trans people by providing a better understanding of long-term outcomes.

This case study details the experience of a detransitioned woman who, after undergoing a chest masculinization mastectomy, became pregnant and experienced profound grief and psychological distress from her inability to breastfeed. The report highlights the lack of informed consent regarding the loss of breastfeeding function, the poor understanding from healthcare providers, and the emotional toll on the mother.

This study of 952 individuals in the US Military Healthcare System tracked continuation/discontinuation rates of cross-sex hormones. While approximately 70% continued hormone use for at least 4 years, the discontinuation rate (desistance) was 30% - substantially higher for transmasculine individuals (35.6% discontinuation) compared to transfeminine (19%). Adults who started hormones after age 18 had a 35.6% discontinuation rate. Notably, nearly 26% (1 in 4) of those who started as minors stopped treatment. These findings suggest desistance rates may be higher than typically cited in the literature and reveal important differences by gender and age at initiation.

This online survey of 237 detransitioners (92% female) found significant unmet needs. Key reasons for detransition included realizing dysphoria was related to other issues (70%), health concerns (62%), and transition not helping dysphoria (50%). Major needs included psychological support for comorbid conditions and regret, medical help for complications, and social connection with other detransitioners. Many reported a lack of support, negative experiences with healthcare providers, and rejection from the LGBT community.

Review of studies showing transgender women retain 9-31% advantages in muscle mass, strength, and hemoglobin post-hormone therapy, due to irreversible male puberty effects.

A UK primary care audit of 68 transgender patients that found no consistent national guidelines for monitoring, leading to substandard care for up to two-thirds of patients. The study revealed long waits for specialist services, high rates of co-occurring mental health conditions, and a 20% rate of hormone cessation, with over half of those stopping citing detransition or regret. The authors call for evidence-based primary care standards.

This case study of a young adult female who detransitioned highlights the complexity of gender identity development. The patient had a history of trauma, autism, and mental health comorbidities. The author emphasizes the need for thorough psychological assessment and a cautious, individualized approach for gender-dysphoric youth, allowing for identity exploration without premature medicalization.

In 175 adults discharged from a UK gender clinic, only 56% finished the planned pathway; 59% got all desired treatments (94% hormones, 48% surgery). 22% dropped out, 19% soon re-referred. Neurodevelopmental conditions, childhood adversity, on-going mental-health or substance problems predicted worse outcomes. Authors urge more individualised, trauma-informed care.

This study reports follow-up data on the largest sample to date of boys clinic-referred for gender dysphoria (n=139). In childhood, the boys were assessed at a mean age of 7.49 years and followed-up at a mean age of 20.58 years. Of the 139 boys, 17 (12.2%) were classified as persisters and 122 (87.8%) as desisters. Data showed boys clinic-referred for gender identity concerns had a high rate of desistance and a high rate of biphilic/androphilic sexual orientation.

This survey of 100 detransitioners (69% female) found varied reasons for detransition, including becoming more comfortable with their natal sex (60%), concerns about medical complications (49%), and realizing their dysphoria was linked to other issues like trauma or mental health conditions (38%). Notably, 23% cited homophobia or difficulty accepting same-sex attraction as a factor. A majority (55%) felt their initial evaluation for transition was inadequate, and only 24% had informed their clinicians of their detransition.

This study proposes the first systematic typology of gender detransition to address inconsistencies in how the concept has been applied by clinicians and researchers. The typology categorizes detransition based on whether individuals cease or continue identifying as transgender after discontinuing transition-related interventions. The author discusses implications for healthcare providers, emphasizing the need for clinical guidelines specifically for detransitioners. The article also explores possibilities for preventing detransition, highlighting the challenges clinicians face when treating individuals with gender dysphoria. Concludes that detransition is an emerging yet poorly understood phenomenon requiring specialized healthcare support and further research.

This paper highlights the growing number of individuals seeking to desist or detransition from a gender transition. The authors argue that despite this trend, there is a significant lack of research, clinical guidance, and support for this population. They note that while extensive protocols exist for transitioning, there are none for those who detransition, and call for urgent attention to clinical and research needs for this cohort.